Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025
1. EFTISARC-NEO Phase II trial relevant for Immutep accepted for oral presentation. 2. Trial evaluates eftilagimod alpha in soft tissue sarcoma alongside KEYTRUDA. 3. Soft tissue sarcoma has high unmet medical need, affecting 13,520 patients in 2025. 4. Oral presentation scheduled for November 13, 2025, at CTOS Annual Meeting. 5. Immutep's LAG-3 research shows potential advancements in cancer treatments.